Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—A meta‐analysis

Introduction The use of molecular markers, especially BRAF and TERT promoter mutations, for risk stratification in papillary thyroid carcinoma (PTC) is subject to continuing debate. In this study, we aimed to investigate the clinicopathological implication of each genotype when combining BRAF and TE...

Full description

Saved in:
Bibliographic Details
Published inClinical endocrinology (Oxford) Vol. 87; no. 5; pp. 411 - 417
Main Authors Vuong, Huy Gia, Altibi, Ahmed M.A., Duong, Uyen N.P., Hassell, Lewis
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.11.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Introduction The use of molecular markers, especially BRAF and TERT promoter mutations, for risk stratification in papillary thyroid carcinoma (PTC) is subject to continuing debate. In this study, we aimed to investigate the clinicopathological implication of each genotype when combining BRAF and TERT promoter mutations in PTCs. Methods We searched four electronic databases including PubMed, Scopus, Web of Science and Virtual Health Library for relevant studies. Pooled estimates of odds ratios and corresponding 95% confidence intervals were calculated using random‐effect model. Results From 111 results, we finally included 11 studies with 3911 PTC patients for meta‐analyses. Our results demonstrated that PTCs with concurrent BRAF and TERT promoter mutations were associated with increased tumour aggressiveness in comparison with PTCs harbouring BRAF or TERT promoter mutation alone. The combination of BRAF and TERT promoter mutations could classify PTCs into four distinct risk groups with decreasing aggressiveness as follows: coexisting BRAF and TERT > TERT alone=BRAF alone > no mutations. Conclusion The risk stratification of PTC based on these four genotypes can help improve the clinical management of PTCs by identifying the group of PTCs with the highest aggressiveness.
AbstractList The use of molecular markers, especially BRAF and TERT promoter mutations, for risk stratification in papillary thyroid carcinoma (PTC) is subject to continuing debate. In this study, we aimed to investigate the clinicopathological implication of each genotype when combining BRAF and TERT promoter mutations in PTCs. We searched four electronic databases including PubMed, Scopus, Web of Science and Virtual Health Library for relevant studies. Pooled estimates of odds ratios and corresponding 95% confidence intervals were calculated using random-effect model. From 111 results, we finally included 11 studies with 3911 PTC patients for meta-analyses. Our results demonstrated that PTCs with concurrent BRAF and TERT promoter mutations were associated with increased tumour aggressiveness in comparison with PTCs harbouring BRAF or TERT promoter mutation alone. The combination of BRAF and TERT promoter mutations could classify PTCs into four distinct risk groups with decreasing aggressiveness as follows: coexisting BRAF and TERT > TERT alone=BRAF alone > no mutations. The risk stratification of PTC based on these four genotypes can help improve the clinical management of PTCs by identifying the group of PTCs with the highest aggressiveness.
INTRODUCTIONThe use of molecular markers, especially BRAF and TERT promoter mutations, for risk stratification in papillary thyroid carcinoma (PTC) is subject to continuing debate. In this study, we aimed to investigate the clinicopathological implication of each genotype when combining BRAF and TERT promoter mutations in PTCs.METHODSWe searched four electronic databases including PubMed, Scopus, Web of Science and Virtual Health Library for relevant studies. Pooled estimates of odds ratios and corresponding 95% confidence intervals were calculated using random-effect model.RESULTSFrom 111 results, we finally included 11 studies with 3911 PTC patients for meta-analyses. Our results demonstrated that PTCs with concurrent BRAF and TERT promoter mutations were associated with increased tumour aggressiveness in comparison with PTCs harbouring BRAF or TERT promoter mutation alone. The combination of BRAF and TERT promoter mutations could classify PTCs into four distinct risk groups with decreasing aggressiveness as follows: coexisting BRAF and TERT > TERT alone=BRAF alone > no mutations.CONCLUSIONThe risk stratification of PTC based on these four genotypes can help improve the clinical management of PTCs by identifying the group of PTCs with the highest aggressiveness.
Introduction The use of molecular markers, especially BRAF and TERT promoter mutations, for risk stratification in papillary thyroid carcinoma (PTC) is subject to continuing debate. In this study, we aimed to investigate the clinicopathological implication of each genotype when combining BRAF and TERT promoter mutations in PTCs. Methods We searched four electronic databases including PubMed, Scopus, Web of Science and Virtual Health Library for relevant studies. Pooled estimates of odds ratios and corresponding 95% confidence intervals were calculated using random‐effect model. Results From 111 results, we finally included 11 studies with 3911 PTC patients for meta‐analyses. Our results demonstrated that PTCs with concurrent BRAF and TERT promoter mutations were associated with increased tumour aggressiveness in comparison with PTCs harbouring BRAF or TERT promoter mutation alone. The combination of BRAF and TERT promoter mutations could classify PTCs into four distinct risk groups with decreasing aggressiveness as follows: coexisting BRAF and TERT > TERT alone=BRAF alone > no mutations. Conclusion The risk stratification of PTC based on these four genotypes can help improve the clinical management of PTCs by identifying the group of PTCs with the highest aggressiveness.
Introduction The use of molecular markers, especially BRAF and TERT promoter mutations, for risk stratification in papillary thyroid carcinoma (PTC) is subject to continuing debate. In this study, we aimed to investigate the clinicopathological implication of each genotype when combining BRAF and TERT promoter mutations in PTCs. Methods We searched four electronic databases including PubMed, Scopus, Web of Science and Virtual Health Library for relevant studies. Pooled estimates of odds ratios and corresponding 95% confidence intervals were calculated using random-effect model. Results From 111 results, we finally included 11 studies with 3911 PTC patients for meta-analyses. Our results demonstrated that PTCs with concurrent BRAF and TERT promoter mutations were associated with increased tumour aggressiveness in comparison with PTCs harbouring BRAF or TERT promoter mutation alone. The combination of BRAF and TERT promoter mutations could classify PTCs into four distinct risk groups with decreasing aggressiveness as follows: coexisting BRAF and TERT > TERT alone=BRAF alone > no mutations. Conclusion The risk stratification of PTC based on these four genotypes can help improve the clinical management of PTCs by identifying the group of PTCs with the highest aggressiveness.
Author Vuong, Huy Gia
Duong, Uyen N.P.
Hassell, Lewis
Altibi, Ahmed M.A.
Author_xml – sequence: 1
  givenname: Huy Gia
  surname: Vuong
  fullname: Vuong, Huy Gia
  email: huyvuong@hotmail.com
  organization: Cho Ray Hospital
– sequence: 2
  givenname: Ahmed M.A.
  orcidid: 0000-0001-7518-5415
  surname: Altibi
  fullname: Altibi, Ahmed M.A.
  organization: University of Jordan
– sequence: 3
  givenname: Uyen N.P.
  surname: Duong
  fullname: Duong, Uyen N.P.
  organization: Pham Ngoc Thach University of Medicine
– sequence: 4
  givenname: Lewis
  surname: Hassell
  fullname: Hassell, Lewis
  organization: University of Oklahoma Health Sciences Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28666074$$D View this record in MEDLINE/PubMed
BookMark eNp1kbtO7DAQhi0Egl2g4AWQpdNAEbDjS5JyWS0XCQFCSx05jsMxiu0cOxFsxyNQ8IQ8CYbAKZCYZqb4_GnG_xSsW2cVAHsYHeFYx1LZI0woJmtggglnSZpytg4miCCUIM7pFpiG8IAQYjnKNsFWmnPOUUYn4OnGu3vrQq8l1KZrtRS9dha6Bp7czk6hsDVcLm6XsPPOuF55aIZ-RKQzlbbjrC3sRKfbVvgV7P-uvNM1lMJLbZ0Rb8-vM2hUH4cXYUW7CjrsgI1GtEHtfvVtcHe6WM7Pk8vrs4v57DKRlFGSpDRDpKgJqRlhqJIkbSpOGyVEkRFcNxXLcSWxogVmqMFNVaQs4zRVNK9kpiTZBgejNx7wb1ChL40OUsVNrXJDKHF8GM2YZxH98wN9cIOP-35QjJGC5VkRqcORkt6F4FVTdl6beHeJUfkRRxnjKD_jiOz-l3GojKr_k9__H4HjEXjUrVr9birni6tR-Q5DaZgK
CitedBy_id crossref_primary_10_1024_1661_8157_a003240
crossref_primary_10_1038_s41598_019_41701_4
crossref_primary_10_3390_cancers11111744
crossref_primary_10_1016_j_prp_2022_154180
crossref_primary_10_3390_biomedicines11041217
crossref_primary_10_2147_TACG_S412364
crossref_primary_10_1159_000520938
crossref_primary_10_3390_cancers12082115
crossref_primary_10_3390_jcm10102179
crossref_primary_10_3390_cancers15020413
crossref_primary_10_1016_j_humpath_2019_09_008
crossref_primary_10_1002_hed_26987
crossref_primary_10_17816_brmma79445
crossref_primary_10_3390_medicina59081488
crossref_primary_10_1007_s10238_024_01320_4
crossref_primary_10_1002_cncy_22454
crossref_primary_10_1007_s00259_019_04557_4
crossref_primary_10_1016_j_mpdhp_2019_02_001
crossref_primary_10_1007_s11154_023_09857_7
crossref_primary_10_1089_thy_2022_0428
crossref_primary_10_1186_s12885_021_08810_8
crossref_primary_10_3389_fendo_2023_1270796
crossref_primary_10_3390_cancers13092048
crossref_primary_10_1007_s11154_023_09852_y
crossref_primary_10_3390_cancers13030470
crossref_primary_10_3390_cancers13040648
crossref_primary_10_1007_s12672_019_0359_8
crossref_primary_10_1007_s12020_019_02140_3
crossref_primary_10_1093_jnci_djad265
crossref_primary_10_1007_s12022_022_09741_1
crossref_primary_10_1007_s40618_023_02063_x
crossref_primary_10_1002_hed_26393
crossref_primary_10_1210_en_2019_00315
crossref_primary_10_17650_2222_1468_2021_11_1_78_85
crossref_primary_10_3390_cancers12082104
crossref_primary_10_1089_thy_2022_0155
crossref_primary_10_1007_s00268_020_05521_2
crossref_primary_10_1093_annonc_mdz400
crossref_primary_10_1210_jc_2019_00177
crossref_primary_10_26442_18151434_2020_4_200507
crossref_primary_10_1186_s13000_019_0849_6
crossref_primary_10_3233_CH_190568
crossref_primary_10_1007_s12022_022_09707_3
crossref_primary_10_1186_s13044_024_00195_7
crossref_primary_10_1042_BSR20202544
crossref_primary_10_1002_cncy_22829
crossref_primary_10_1002_jso_26380
crossref_primary_10_1016_j_ijporl_2022_111121
crossref_primary_10_3390_jpm14060654
crossref_primary_10_1111_apm_13267
crossref_primary_10_1007_s10585_019_10011_4
crossref_primary_10_3390_biomedicines11041075
crossref_primary_10_1007_s12020_022_03267_6
crossref_primary_10_1097_MD_0000000000029341
crossref_primary_10_1016_j_asjsur_2021_09_014
crossref_primary_10_11106_ijt_2024_17_1_68
crossref_primary_10_2478_amb_2021_0001
crossref_primary_10_1186_s12964_019_0372_0
crossref_primary_10_11106_ijt_2023_16_1_89
crossref_primary_10_3390_jcm10112438
crossref_primary_10_1016_j_amjoto_2021_103278
crossref_primary_10_1097_JS9_0000000000001117
crossref_primary_10_1007_s00432_022_04541_w
crossref_primary_10_1007_s12022_020_09643_0
crossref_primary_10_1186_s12885_020_07364_5
crossref_primary_10_3390_cells9030749
crossref_primary_10_3390_ijms20061334
crossref_primary_10_1007_s12020_020_02438_7
crossref_primary_10_3389_fendo_2020_00102
crossref_primary_10_3390_cancers12082164
crossref_primary_10_3390_cancers15164053
crossref_primary_10_14639_0392_100X_N0608
crossref_primary_10_1111_cen_14316
crossref_primary_10_1007_s40619_020_00718_y
crossref_primary_10_1089_ct_2021_33_403_405
crossref_primary_10_1530_EC_18_0333
crossref_primary_10_1007_s11154_019_09491_2
crossref_primary_10_1507_endocrj_EJ20_0063
crossref_primary_10_1007_s00259_022_05820_x
crossref_primary_10_1089_thy_2018_0314
crossref_primary_10_17816_brmma64670
crossref_primary_10_1007_s11427_018_9546_5
crossref_primary_10_3389_fonc_2020_549882
Cites_doi 10.1530/EJE-14-0837
10.1089/thy.2015.0020
10.1210/jc.2013-4048
10.1002/sim.1186
10.1002/cncr.29934
10.1210/jc.2012-2104
10.1089/thy.2016.0350
10.1001/jamaoto.2014.1
10.1530/ERC-16-0402
10.1371/journal.pmed.1000097
10.1002/cncr.26500
10.1530/ERC-13-0210
10.1001/jama.2013.3190
10.1038/srep36990
10.1007/s12672-016-0256-3
10.1126/science.1230062
10.1210/jc.2012-1775
10.1089/thy.2015.0488
10.1210/jc.2013-3734
10.1200/JCO.2014.55.5094
10.1371/journal.pone.0153319
10.1210/jc.2012-1526
10.1089/thy.2015.0101
10.18632/oncotarget.7811
10.1002/jso.20700
10.1007/s00428-016-2027-5
ContentType Journal Article
Copyright 2017 John Wiley & Sons Ltd
2017 John Wiley & Sons Ltd.
Copyright © 2017 John Wiley & Sons Ltd
Copyright_xml – notice: 2017 John Wiley & Sons Ltd
– notice: 2017 John Wiley & Sons Ltd.
– notice: Copyright © 2017 John Wiley & Sons Ltd
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
K9.
NAPCQ
7X8
DOI 10.1111/cen.13413
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Calcium & Calcified Tissue Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1365-2265
EndPage 417
ExternalDocumentID 10_1111_cen_13413
28666074
CEN13413
Genre reviewArticle
Meta-Analysis
Journal Article
Review
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
08P
0R~
10A
1OB
1OC
29B
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAKAS
AANLZ
AAONW
AAQQT
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHEFC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
DUUFO
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
J5H
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MJL
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
REN
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TEORI
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
X7M
XG1
YOC
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
CGR
CUY
CVF
ECM
EIF
NPM
AAMNL
AAYXX
ACRPL
ACYXJ
CITATION
7QP
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c4543-247039d33d5350bc32fb64feaa9731dfb581bc1e49150f1fb9257642e48bc7ec3
IEDL.DBID DR2
ISSN 0300-0664
IngestDate Wed Dec 04 15:47:45 EST 2024
Tue Nov 19 04:12:28 EST 2024
Fri Dec 06 01:04:48 EST 2024
Sat Sep 28 08:39:51 EDT 2024
Sat Aug 24 01:02:04 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords meta-analysis
BRAF V600E
papillary thyroid carcinoma
review
BRAF mutation
TERT promoter
Language English
License 2017 John Wiley & Sons Ltd.
http://onlinelibrary.wiley.com/termsAndConditions#vor
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4543-247039d33d5350bc32fb64feaa9731dfb581bc1e49150f1fb9257642e48bc7ec3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ORCID 0000-0001-7518-5415
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cen.13413
PMID 28666074
PQID 1955395879
PQPubID 36523
PageCount 7
ParticipantIDs proquest_miscellaneous_1915350167
proquest_journals_1955395879
crossref_primary_10_1111_cen_13413
pubmed_primary_28666074
wiley_primary_10_1111_cen_13413_CEN13413
PublicationCentury 2000
PublicationDate November 2017
PublicationDateYYYYMMDD 2017-11-01
PublicationDate_xml – month: 11
  year: 2017
  text: November 2017
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
PublicationTitle Clinical endocrinology (Oxford)
PublicationTitleAlternate Clin Endocrinol (Oxf)
PublicationYear 2017
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2016; 6
2015; 172
2015; 25
2016; 7
2006; 94
2013; 339
2013; 309
2013; 20
2002; 21
2017; 24
2016; 122
2017
2016; 469
2016
2014; 140
2009; 6
2015
2016; 26
2012; 118
2014; 99
2012; 97
2014; 32
2016; 11
e_1_2_6_10_1
e_1_2_6_30_1
Liu R (e_1_2_6_29_1) 2016
e_1_2_6_19_1
e_1_2_6_13_1
e_1_2_6_11_1
e_1_2_6_12_1
e_1_2_6_17_1
e_1_2_6_18_1
e_1_2_6_15_1
e_1_2_6_16_1
Van Rhee HJ (e_1_2_6_14_1) 2015
e_1_2_6_21_1
e_1_2_6_20_1
e_1_2_6_9_1
e_1_2_6_8_1
e_1_2_6_5_1
e_1_2_6_4_1
e_1_2_6_7_1
e_1_2_6_6_1
e_1_2_6_25_1
e_1_2_6_24_1
e_1_2_6_3_1
e_1_2_6_23_1
e_1_2_6_2_1
e_1_2_6_22_1
e_1_2_6_28_1
e_1_2_6_27_1
e_1_2_6_26_1
References_xml – volume: 99
  start-page: E1130
  year: 2014
  end-page: E1136
  article-title: TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer
  publication-title: J Clin Endocrinol Metab
– volume: 118
  start-page: 1764
  year: 2012
  end-page: 1773
  article-title: The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta‐analysis
  publication-title: Cancer
– volume: 7
  start-page: 165
  year: 2016
  end-page: 177
  article-title: TERT promoter mutations in thyroid cancer
  publication-title: Hormones Cancer
– start-page: 651
  year: 2017
  end-page: 660
  article-title: Effects of coexistent BRAFV600E and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: a meta‐analysis
  publication-title: Thyroid
– volume: 24
  start-page: 41
  year: 2017
  end-page: 52
  article-title: A six‐genotype genetic prognostic model for papillary thyroid cancer
  publication-title: Endocr Relat Cancer
– volume: 172
  start-page: 403
  year: 2015
  end-page: 413
  article-title: TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma
  publication-title: Eur J Endocrinol
– volume: 339
  start-page: 959
  year: 2013
  end-page: 961
  article-title: TERT promoter mutations in familial and sporadic melanoma
  publication-title: Science
– volume: 309
  start-page: 1493
  year: 2013
  end-page: 1501
  article-title: Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer
  publication-title: JAMA
– volume: 140
  start-page: 317
  year: 2014
  end-page: 322
  article-title: Current thyroid cancer trends in the United States
  publication-title: JAMA Otolaryngol Head Neck Surg
– volume: 94
  start-page: 662
  year: 2006
  end-page: 669
  article-title: Pathology and genetics of thyroid carcinoma
  publication-title: J Surg Oncol
– volume: 25
  start-page: 1013
  year: 2015
  end-page: 1019
  article-title: TERT promoter mutations in papillary thyroid microcarcinomas
  publication-title: Thyroid
– volume: 122
  start-page: 1370
  year: 2016
  end-page: 1379
  article-title: Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients
  publication-title: Cancer
– volume: 32
  start-page: 2718
  year: 2014
  end-page: 2726
  article-title: BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence
  publication-title: J Clin Oncol
– volume: 97
  start-page: E1745
  year: 2012
  end-page: E1749
  article-title: BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas
  publication-title: J Clin Endocrinol Metab
– volume: 26
  start-page: 901
  year: 2016
  end-page: 910
  article-title: Prognostic significance of TERT promoter mutations in papillary thyroid carcinomas in a BRAF(V600E) mutation‐prevalent population
  publication-title: Thyroid
– volume: 21
  start-page: 1539
  year: 2002
  end-page: 1558
  article-title: Quantifying heterogeneity in a meta‐analysis
  publication-title: Stat Med
– volume: 6
  start-page: 36990
  year: 2016
  article-title: TERT promoter mutation and its association with clinicopathological features and prognosis of papillary thyroid cancer: a meta‐analysis
  publication-title: Sci Rep
– volume: 97
  start-page: 4390
  year: 2012
  end-page: 4398
  article-title: The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low‐risk intrathyroid papillary thyroid carcinoma: single‐institution results from a large cohort study
  publication-title: J Clin Endocrinol Metab
– volume: 11
  start-page: e0153319
  year: 2016
  article-title: BRAF V600E and TERT promoter mutations in papillary thyroid carcinoma in Chinese patients
  publication-title: PLoS One
– volume: 97
  start-page: 4559
  year: 2012
  end-page: 4570
  article-title: BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta‐analysis
  publication-title: J Clin Endocrinol Metab
– volume: 7
  start-page: 18346
  year: 2016
  end-page: 18355
  article-title: BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients
  publication-title: Oncotarget
– volume: 26
  start-page: 1
  year: 2016
  end-page: 133
  article-title: 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer
  publication-title: Thyroid
– volume: 6
  start-page: e1000097
  year: 2009
  article-title: Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement
  publication-title: PLoS Med
– volume: 469
  start-page: 687
  year: 2016
  end-page: 696
  article-title: In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation
  publication-title: Virchows Arch
– volume: 99
  start-page: E754
  year: 2014
  end-page: E765
  article-title: TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas
  publication-title: J Clin Endocrinol Metab
– volume: 20
  start-page: 603
  year: 2013
  end-page: 610
  article-title: Highly prevalent TERT promoter mutations in aggressive thyroid cancers
  publication-title: Endocr Relat Cancer
– year: 2015
– start-page: 202
  year: 2016
  end-page: 208
  article-title: Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality
  publication-title: JAMA Oncol
– ident: e_1_2_6_9_1
  doi: 10.1530/EJE-14-0837
– ident: e_1_2_6_22_1
  doi: 10.1089/thy.2015.0020
– ident: e_1_2_6_17_1
  doi: 10.1210/jc.2013-4048
– ident: e_1_2_6_13_1
  doi: 10.1002/sim.1186
– volume-title: User Manual for Meta‐Essentials: Workbooks for Meta‐Analysis (Version 1.0)
  year: 2015
  ident: e_1_2_6_14_1
  contributor:
    fullname: Van Rhee HJ
– ident: e_1_2_6_20_1
  doi: 10.1002/cncr.29934
– ident: e_1_2_6_24_1
  doi: 10.1210/jc.2012-2104
– ident: e_1_2_6_30_1
  doi: 10.1089/thy.2016.0350
– ident: e_1_2_6_2_1
  doi: 10.1001/jamaoto.2014.1
– ident: e_1_2_6_19_1
  doi: 10.1530/ERC-16-0402
– ident: e_1_2_6_11_1
  doi: 10.1371/journal.pmed.1000097
– ident: e_1_2_6_23_1
  doi: 10.1002/cncr.26500
– ident: e_1_2_6_6_1
  doi: 10.1530/ERC-13-0210
– ident: e_1_2_6_4_1
  doi: 10.1001/jama.2013.3190
– ident: e_1_2_6_27_1
  doi: 10.1038/srep36990
– ident: e_1_2_6_25_1
  doi: 10.1007/s12672-016-0256-3
– ident: e_1_2_6_26_1
  doi: 10.1126/science.1230062
– ident: e_1_2_6_7_1
  doi: 10.1210/jc.2012-1775
– ident: e_1_2_6_10_1
  doi: 10.1089/thy.2015.0488
– ident: e_1_2_6_5_1
  doi: 10.1210/jc.2013-3734
– ident: e_1_2_6_8_1
  doi: 10.1200/JCO.2014.55.5094
– ident: e_1_2_6_21_1
  doi: 10.1371/journal.pone.0153319
– ident: e_1_2_6_28_1
  doi: 10.1210/jc.2012-1526
– start-page: 202
  year: 2016
  ident: e_1_2_6_29_1
  article-title: Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality
  publication-title: JAMA Oncol
  contributor:
    fullname: Liu R
– ident: e_1_2_6_15_1
  doi: 10.1089/thy.2015.0101
– ident: e_1_2_6_16_1
  doi: 10.18632/oncotarget.7811
– ident: e_1_2_6_3_1
  doi: 10.1002/jso.20700
– ident: e_1_2_6_12_1
– ident: e_1_2_6_18_1
  doi: 10.1007/s00428-016-2027-5
SSID ssj0005807
Score 2.5728376
SecondaryResourceType review_article
Snippet Introduction The use of molecular markers, especially BRAF and TERT promoter mutations, for risk stratification in papillary thyroid carcinoma (PTC) is subject...
The use of molecular markers, especially BRAF and TERT promoter mutations, for risk stratification in papillary thyroid carcinoma (PTC) is subject to...
Introduction The use of molecular markers, especially BRAF and TERT promoter mutations, for risk stratification in papillary thyroid carcinoma (PTC) is subject...
INTRODUCTIONThe use of molecular markers, especially BRAF and TERT promoter mutations, for risk stratification in papillary thyroid carcinoma (PTC) is subject...
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 411
SubjectTerms BRAF mutation
BRAF V600E
Carcinoma, Papillary - diagnosis
Carcinoma, Papillary - genetics
Genotypes
Humans
Meta-analysis
Mutation
Papillary thyroid carcinoma
Prognosis
Promoter Regions, Genetic - genetics
Proto-Oncogene Proteins B-raf - genetics
review
Risk Assessment - methods
Risk groups
Telomerase - genetics
TERT promoter
Thyroid
Thyroid cancer
Thyroid Cancer, Papillary
Thyroid Neoplasms - diagnosis
Thyroid Neoplasms - genetics
Tumors
Title Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—A meta‐analysis
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcen.13413
https://www.ncbi.nlm.nih.gov/pubmed/28666074
https://www.proquest.com/docview/1955395879
https://search.proquest.com/docview/1915350167
Volume 87
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB5CDiWXPpI-3CZBLT304mWtl2162iZZQqGhhARyKBhJlmApay_OLjQ59Sf00F_YX9IZPzaPUii9CSQjW5qRvvHMfAPw1vhMhkQkscb7KJbC-dhmqO468-NxsJK8aRRtcaKPz-XHC3WxAe-HXJiOH2L9w400oz2vScGNvbyl5M5XI2IjI6bPRKQUznd4ekMdpfpUaUGZ01rLnlWIonjWT969i_4AmHfxanvhTB_Bl-FVuziTr6PV0o7c9T0Wx__8lsfwsAeibNJJzhPY8NU2PPjUu9p34NvnpqYgPOxms5uwc1YH9uF0MmWmKhlC4TO2aAP6fMPmq86tz3B2tLe79qxiC7Og0kbNFUOhaOpZyRwVMKrqufn1_eeEzf0SGz9MT4_yFM6nR2cHx3FfpiF2UkkRc4mnRl4KUSqhxtYJHqyWwRtDZbHKYBVCY5d4mSP4DEmwORk5knuZWZd6J57BZlVX_gUw53WqEQFy54jj1BgjSx6C48HInPtxBG-GDSsWHRtHMVgxuIZFu4YR7A5bWfQKeVkkuVIiV1maR_B63Y2qRP4RU_l6RWMS-oJEpxE870RgPQvP0M5DuBXBu3Yj_z59cXB00jZe_vvQV7DFCS60OY67sLlsVn4Pwc7S7rdS_RuYtfvG
link.rule.ids 314,780,784,1375,27924,27925,46294,46718
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LixQxEC7WFdSL70frqlE8eOlhOq_pBi_jusOou4Mss7AXaZJ0AoNM99DOgHryJ3jwF_pLrOrHrKsI4i2QNOkkVcmXVNVXAM-MT2VIRBJrPI9iKZyPbYrqrlM_HAYryZpG3hYzPT2Rb07V6Q686GNhWn6I7YMbaUazX5OC04P0L1rufDkgOjJxAS6iuifk0PXq-Iw8SnXB0oJip7WWHa8Q-fFsPz1_Gv0BMc8j1ubImVyD9_3Ptp4mHwabtR24L7_xOP7vaK7D1Q6LsnErPDdgx5c34dJRZ22_BZ_e1RX54WE1W5x5nrMqsJfH4wkzZcEQDc_ZqvHp8zVbblrLPsPu8crdlhclW5kVZTeqPzOUi7paFMxRDqOyWpofX7-P2dKvsfDNdAwpt-FkcjDfn8ZdpobYSSVFzCVuHFkhRKGEGloneLBaBm8MZcYqglWIjl3iZYb4MyTBZnTPkdzL1LqRd-IO7JZV6e8Bc16PNIJA7hzRnBpjZMFDcDwYmXE_jOBpv2L5qiXkyPuLDM5h3sxhBHv9WuadTn7Mk0wpkal0lEXwZFuN2kQmElP6akNtEhpBokcR3G1lYNsLT_Gqh4grgufNSv69-3z_YNYU7v9708dweTo_OswPX8_ePoArnNBDE_K4B7vreuMfIvZZ20eNiP8EVzj_5w
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlVceD8CBQziwCWrjV-biNPSdlVeq6pqpR6QItuxpRXaJAq7EnDiJ3DgF_JLmMljS0FIiJslO3Jiz9jfZGa-AXhmfCpDIpJY430US-F8bFNUd5368ThYSd40iraY68NT-fpMnW3BiyEXpuOH2PxwI81oz2tS8LoIvyi58-WI2MjEJbgsNc-IOH__-Jw7SvW50oJSp7WWPa0QhfFsHr14Gf2BMC8C1vbGmV2D98O7doEmH0brlR25L7_ROP7nx1yHqz0SZdNOdG7Ali9vws673td-Cz4dNRVF4WE3W5zHnbMqsJfH0xkzZcEQC5-wuo3o8w1brju_PsPZ0eDu2ouS1aam2kbNZ4ZS0VSLgjmqYFRWS_Pj6_cpW_oVNr6Znh_lNpzODk72DuO-TkPspJIi5hKPjawQolBCja0TPFgtgzeG6mIVwSrExi7xMkP0GZJgM7JyJPcytW7inbgD22VV-nvAnNcTjRCQO0ckp8YYWfAQHA9GZtyPI3g6bFhed3Qc-WDG4Brm7RpGsDtsZd5r5Mc8yZQSmUonWQRPNt2oS-QgMaWv1jQmoS9I9CSCu50IbGbhKRp6iLcieN5u5N-nz_cO5m3j_r8PfQw7R_uz_O2r-ZsHcIUTdGjzHXdhe9Ws_UMEPiv7qBXwn2Jt_pY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+implication+of+BRAF+and+TERT+promoter+mutation+combination+in+papillary+thyroid+carcinoma%E2%80%94A+meta%E2%80%90analysis&rft.jtitle=Clinical+endocrinology+%28Oxford%29&rft.au=Vuong%2C+Huy+Gia&rft.au=Altibi%2C+Ahmed+M.A.&rft.au=Duong%2C+Uyen+N.P.&rft.au=Hassell%2C+Lewis&rft.date=2017-11-01&rft.issn=0300-0664&rft.eissn=1365-2265&rft.volume=87&rft.issue=5&rft.spage=411&rft.epage=417&rft_id=info:doi/10.1111%2Fcen.13413&rft.externalDBID=10.1111%252Fcen.13413&rft.externalDocID=CEN13413
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-0664&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-0664&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-0664&client=summon